中国肿瘤临床
中國腫瘤臨床
중국종류림상
CHINESE JOURNAL OF CLINICAL ONCOLOGY
2014年
13期
836-839
,共4页
王立茹%陈以娟%李星%郭天娇%李茜%路瑾%黄晓军
王立茹%陳以娟%李星%郭天嬌%李茜%路瑾%黃曉軍
왕립여%진이연%리성%곽천교%리천%로근%황효군
多发性骨髓瘤%乙型肝炎病毒%化疗%再激活%硼替佐米
多髮性骨髓瘤%乙型肝炎病毒%化療%再激活%硼替佐米
다발성골수류%을형간염병독%화료%재격활%붕체좌미
multiple myeloma%hepatitis B virus%chemotherapy%reactivation%bortezomib
目的:比较乙型肝炎病毒(HBV)在多发性骨髓瘤(MM)患者中的感染率有无增加,及合并HBV感染MM患者的临床特征。方法:以363例MM患者为研究对象,同时期11227例健康体检者为对照组。采用免疫发光法检测HBV血清学标志物,实时定量聚合酶链反应检测HBV-DNA。比较HBsAg阳性和HBsAg阴性MM患者的临床特征及OS。结果:化疗前16例(4.4%)MM患者HBsAg阳性,高于同期健康体检者(2.4%,P=0.015)。HBsAg阳性与HBsAg阴性MM患者相比,两组MM患者的总生存期无显著差别。2例接受含硼替佐米和地塞米松方案治疗的HBsAg阳性患者化疗后出现肝功异常和HBV再激活,应用抗乙肝药物可以抑制其HBV复制。结论:MM患者具有较体检人群高的HBV感染率,在治疗过程中需要密切监测HBsAg阳性患者的HBV复制并予以抗乙肝治疗。
目的:比較乙型肝炎病毒(HBV)在多髮性骨髓瘤(MM)患者中的感染率有無增加,及閤併HBV感染MM患者的臨床特徵。方法:以363例MM患者為研究對象,同時期11227例健康體檢者為對照組。採用免疫髮光法檢測HBV血清學標誌物,實時定量聚閤酶鏈反應檢測HBV-DNA。比較HBsAg暘性和HBsAg陰性MM患者的臨床特徵及OS。結果:化療前16例(4.4%)MM患者HBsAg暘性,高于同期健康體檢者(2.4%,P=0.015)。HBsAg暘性與HBsAg陰性MM患者相比,兩組MM患者的總生存期無顯著差彆。2例接受含硼替佐米和地塞米鬆方案治療的HBsAg暘性患者化療後齣現肝功異常和HBV再激活,應用抗乙肝藥物可以抑製其HBV複製。結論:MM患者具有較體檢人群高的HBV感染率,在治療過程中需要密切鑑測HBsAg暘性患者的HBV複製併予以抗乙肝治療。
목적:비교을형간염병독(HBV)재다발성골수류(MM)환자중적감염솔유무증가,급합병HBV감염MM환자적림상특정。방법:이363례MM환자위연구대상,동시기11227례건강체검자위대조조。채용면역발광법검측HBV혈청학표지물,실시정량취합매련반응검측HBV-DNA。비교HBsAg양성화HBsAg음성MM환자적림상특정급OS。결과:화료전16례(4.4%)MM환자HBsAg양성,고우동기건강체검자(2.4%,P=0.015)。HBsAg양성여HBsAg음성MM환자상비,량조MM환자적총생존기무현저차별。2례접수함붕체좌미화지새미송방안치료적HBsAg양성환자화료후출현간공이상화HBV재격활,응용항을간약물가이억제기HBV복제。결론:MM환자구유교체검인군고적HBV감염솔,재치료과정중수요밀절감측HBsAg양성환자적HBV복제병여이항을간치료。
To explore the prevalence of hepatitis B virus (HBV) in multiple myeloma (MM) patients, as well as to compare the clinical characteristics and outcome between HBV infected and non-HBV infected patients. Methods:The serology markers of HBV were detected in 363 MM patients and 11227 cases of healthy controls through chemiluminescence. HBV-DNA was measured via real-time quantitative chain reaction. Results:Sixteen out of 363 MM patients (4.4%) were HBsAg-positive, showing significant difference with healthy controls (2.4%). No statistically significant differences were observed in terms of sex, age, type of monoclonal (M) protein, International Staging System (ISS) stage, stem cell transplantation, and risk stratification between HBsAg-positive and HBsAg-negative patients. No significant effect of HBV infection was found on the OS of MM patients. HBV reactivation was observed in two HBsAg-positive MM patients who were treated with combination chemotherapy, including bortezomib and dexamethasone. The replication of HBV could be inhibited by anti-HBV drugs. Conclusion:A higher prevalence of HBV infection was revealed in MM patients. Close monitoring of HBV replication should be conducted in MM patients with HBV infection before and during the courses of chemotherapy.